ReviewVaccine2018
The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships.
Review in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Protection from killed whole-cell cholera vaccines: a systematic review and meta-analysis.The Lancet. Global health · 2025Pooled it
- Attenuating ETEC virulence using a heat-labile enterotoxin-blocking binding protein.Gut microbes · 2026Article
- 5-Year effectiveness of an oral cholera vaccine in a cholera outbreak in rural Haiti: a case-control study.Lancet regional health. Americas · 2026Article
- Global vaccine development.Nature medicine · 2026Review
- Recent epidemiological and management approaches for cholera in India.Proceedings (Baylor University. Medical Center) · 2026Review
- Regulatory Strengthening as a Pillar of Health System Resilience for Sustainable Immunization.Vaccines · 2025Article
- Article
- Navigating the cholera elimination roadmap in Zambia - A scoping review (2013-2024).PLoS neglected tropical diseases · 2025Article
- Evaluation of oral cholera vaccine (Euvichol-Plus) effectiveness againstBMJ global health · 2025Article
- The 30-year evolution of oral cholera vaccines: A case study of a collaborative network alternative innovation model.PLOS global public health · 2025Article
- Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.Pharmaceutics · 2024Review
- Participatory Disease Surveillance for the Early Detection of Cholera-Like Diarrheal Disease Outbreaks in Rural Villages in Malawi: Prospective Cohort Study.JMIR public health and surveillance · 2024Article
- Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study.The Lancet. Infectious diseases · 2024Article
- Cholera rages in Africa and the Middle East: A narrative review on challenges and solutions.Health science reports · 2024Review
- Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions.Cell & bioscience · 2024Review
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- Effectiveness of the Euvichol® oral cholera vaccine at 2 years: A case-control and bias-indicator study in Haiti.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- MucoRice-CTB line 19A, a new marker-free transgenic rice-based cholera vaccine produced in an LED-based hydroponic system.Frontiers in plant science · 2024Article
- Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.The Lancet regional health. Southeast Asia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera, a diarrheal disease primarily affecting vulnerable populations in developing countries, is estimated to cause disease in more than 2.5 million people and kill almost 100,000 annually. An oral cholera vaccine (OCV) has been available globally since 2001; the demand for this vaccine from affected countries has however been very low, due to various factors including vaccine price and mode of administration. The low demand for the vaccine and limited commercial incentives to invest in research and development of vaccines for developing country markets has kept the global supply of OCVs down. Since 1999, the International Vaccine Institute has been committed to make safe, effective and affordable OCVs accessible. Through a variety of partnerships with collaborators in Sweden, Vietnam, India and South Korea, and with public and private funding, IVI facilitated development and production of two affordable and WHO-prequalified OCVs and together with other stakeholders accelerated the introduction of these vaccines for the global public-sector market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.